PLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Protalix Biotherapeutics Inc (PLX) is not a good buy for a beginner, long-term investor at this moment. The company's financial performance is weak, with significant declines in revenue, net income, and gross margin. Additionally, there are no strong positive catalysts, and trading signals do not indicate a strong buy opportunity. The technical indicators are neutral, and options data shows low put-call ratios, but this is not enough to justify a buy recommendation given the broader context.
The MACD is positive and expanding, indicating a slight bullish momentum. RSI is neutral at 59.204, and moving averages are converging, suggesting no clear trend. Key resistance levels are at 2.272 and 2.333, with support at 2.173 and 2.073. Overall, the technical indicators are neutral with no strong buy signal.
NULL identified. There are no recent news events, insider trades, hedge fund activity, or congress trading data to act as positive catalysts.
The company's financial performance is significantly deteriorating, with a YoY revenue drop of -49.93%, net income down -184.76%, and gross margin down -1344.71%. Additionally, there are no recent analyst upgrades or positive sentiment from influential figures.
In Q4 2025, revenue dropped to $9.12M (-49.93% YoY), net income fell to -$5.5M (-184.76% YoY), EPS declined to -0.08 (-233.33% YoY), and gross margin plummeted to -979.21% (-1344.71% YoY). These metrics indicate severe financial underperformance.
No recent analyst ratings or price target changes are available for PLX.
